These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7856614)

  • 21. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis.
    Messori A; Rampazzo R; Scroccaro G; Martini N
    Bone Marrow Transplant; 1994 Feb; 13(2):163-7. PubMed ID: 8205085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation.
    Meyers JD; Leszczynski J; Zaia JA; Flournoy N; Newton B; Snydman DR; Wright GG; Levin MJ; Thomas ED
    Ann Intern Med; 1983 Apr; 98(4):442-6. PubMed ID: 6301320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune globulin therapy in allogeneic bone marrow transplant: a critical review.
    Guglielmo BJ; Wong-Beringer A; Linker CA
    Bone Marrow Transplant; 1994 May; 13(5):499-510. PubMed ID: 8054903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group.
    Werner BG; Snydman DR; Freeman R; Rohrer R; Tilney NL; Kirkman RL
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1441-3. PubMed ID: 8382875
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA approves marketing of cytomegalovirus immune globulin.
    Clin Pharm; 1990 Jul; 9(7):493. PubMed ID: 2165448
    [No Abstract]   [Full Text] [Related]  

  • 27. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
    Puius YA; Snydman DR
    Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus immune globulin.
    Med Lett Drugs Ther; 1988 Oct; 30(777):100. PubMed ID: 2845236
    [No Abstract]   [Full Text] [Related]  

  • 29. Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis.
    Arbo MD; Snydman DR; Wong JB; Goldberg HS; Schmid CH; Pauker SG
    Clin Transplant; 2000 Feb; 14(1):19-27. PubMed ID: 10693631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic use of immunoglobulin in bone marrow transplantation.
    Ho WG; Winston DJ; Champlin RE; Gale RP
    Int J Cell Cloning; 1986; 4 Suppl 1():174-80. PubMed ID: 3018101
    [No Abstract]   [Full Text] [Related]  

  • 31. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease.
    Glowacki LS; Smaill FM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1408-10. PubMed ID: 8382863
    [No Abstract]   [Full Text] [Related]  

  • 32. Cytomegalovirus prophylaxis strategies in high-risk transplantation.
    Snydman DR
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):20-2. PubMed ID: 7940971
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of cytomegalovirus immune globulin.
    Snydman DR
    Clin Pharm; 1992 Aug; 11(8):674-5. PubMed ID: 1324822
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytomegalovirus infection in seromismatched lung transplant recipients with and without prophylaxis with CMV immunoglobulin.
    Kathawalla SA; Stillwell PC; Gordon S; Haug M; Perl M; Arroliga AC; Mehta AC; Avery R; Kirby T
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):16. PubMed ID: 9037272
    [No Abstract]   [Full Text] [Related]  

  • 35. Defining an optimal regimen for cytomegalovirus prophylaxis in organ transplant recipients.
    Paya CV
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):9-11. PubMed ID: 9037269
    [No Abstract]   [Full Text] [Related]  

  • 36. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients.
    Snydman DR
    Transplant Proc; 1993 Oct; 25(5 Suppl 4):25-6. PubMed ID: 8212304
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment?
    Tenschert W; Gonnermann D; Meyer-Moldenhauer WH; Cremaschi L; Huland H
    Transplant Proc; 1993 Dec; 25(6):3256-8. PubMed ID: 8266533
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors.
    Meijer E; Dekker AW; Rozenberg-Arska M; Weersink AJ; Verdonck LF
    Clin Infect Dis; 2002 Sep; 35(6):703-12. PubMed ID: 12203168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
    Conti DJ; Freed BM; Lempert N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
    [No Abstract]   [Full Text] [Related]  

  • 40. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.